Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Epizyme revenue
Epizyme's revenue is $37.4 million.
What is Epizyme's revenue?
- Epizyme's revenue growth from 2012 to 2021 is -17.24%.
- Epizyme has 124 employees, and the revenue per employee ratio is $301,830.
- Epizyme's peak quarterly revenue was $36.3M in 2013(q4).
- Epizyme peak revenue was $68.5M in 2013.
- Epizyme annual revenue for 2020 was 15.8M, -33.77% growth from 2019.
- Epizyme annual revenue for 2021 was 37.4M, 137.45% growth from 2020.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Epizyme historical revenue
Epizyme's peak revenue was $68.5M in 2013. The peak quarterly revenue was $36.3M in 2013(q4).
Epizyme's revenue increased from $45.2m in 2012 to $37.4M currently. That's a -17.24% change in annual revenue.
Epizyme annual revenue
Epizyme annual revenue over time
| Fiscal year / year | Epizyme revenue |
|---|---|
| 2012 | $45.2M |
| 2013 | $68.5M |
| 2014 | $41.4M |
| 2015 | $2.6M |
| 2016 | $8.0M |
| 2017 | $10.0M |
| 2018 | $21.7M |
| 2019 | $23.8M |
| 2020 | $15.8M |
| 2021 | $37.4M |
Rate Epizyme's financial transparency
Epizyme annual growth
Epizyme saw the greatest revenue growth in 2016, when revenue increased by 212.77%.
Epizyme had the lowest revenue growth in 2015, when revenue changed by -93.82%.
Epizyme annual growth rate over time
| Year | Epizyme growth |
|---|---|
| 2013 | 51%↑ |
| 2014 | -40%↓ |
| 2015 | -94%↓ |
| 2016 | 213%↑ |
| 2017 | 25%↑ |
| 2018 | 117%↑ |
| 2019 | 10%↑ |
| 2020 | -34%↓ |
| 2021 | 137%↑ |
Epizyme quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Epizyme quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | $14.8M | $8.4M | $36.3M |
| 2014 | $13.4M | $9.5M | $8.2M | $10.3M |
| 2015 | $911,000 | $736,000 | $358,000 | $555,000 |
| 2016 | $472,000 | $473,000 | $6.6M | $478,000 |
| 2017 | - | $10.0M | - | - |
| 2018 | - | $12.0M | - | $9.7M |
| 2019 | $7.9M | $5.9M | $5.7M | $4.3M |
| 2020 | $1.4M | $2.5M | $3.6M | $8.4M |
| 2021 | $7.6M | $13.0M | $5.2M | $11.6M |
| 2022 | $8.7M | $27.5M | - | - |
Epizyme jobs nearby
Do you work at Epizyme?
Is Epizyme transparent about its revenue structure?
Epizyme financial information
| CEO | Grant C. Bogle |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 124 |
| Date Founded | 2007 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 1 |
| Revenue | $37.4M |
| Net Income | -$251,122,000 |
| Gross Proft | $26.9M (2021) |
| PE Ratio | -4.62 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.2B |
| Total Assets | $289,000,000 |
| Ticker | EPZM |
Epizyme jobs you might like
Epizyme financing
Epizyme received early financing of $32.0M on 2009-10-07.
| Series | Round size | Date |
|---|---|---|
| Series B | $32M | 10/2009 |
| Series B | $8M | 12/2009 |
| Grant | $733K | 11/2010 |
| Grant | $1M | 01/2011 |
| Series Unknown | $7.5M | 06/2011 |
| Series Unknown | $4M | 10/2011 |
| Post Ipo Equity | $10M | 02/2014 |
| Post Ipo Equity | $130.7M | 03/2015 |
| Post Ipo Equity | $130.1M | 01/2016 |
| Post Ipo Equity | $151.3M | 09/2017 |
| Post Ipo Equity | $86.3M | 10/2018 |
| Post Ipo Equity | $172.5M | 03/2019 |
| Post Ipo Equity | $100M | 11/2019 |
Epizyme investors
| Investors | Security type |
|---|---|
| Bay City Capital | Series B |
| Astellas Venture Management LLC | Series B |
| MPM Capital | Series B |
| Kleiner Perkins | Series B |
| Amgen Inc. | Series B |
| New Enterprise Associates (NEA) | Series B |
| Multiple Myeloma Research Foundation MMRF | Grant |
| The Leukemia & Lymphoma Society | Series Unknown |
| GSK PLC | Series Unknown |
| CELGENE CORP DE | Post Ipo Equity |
| ROYALTY PHARMA PLC | Post Ipo Equity |
Search for jobs
Epizyme highest paying jobs
Zippia gives an in-depth look into the details of Epizyme, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Epizyme. The employee data is based on information from people who have self-reported their past or current employments at Epizyme. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Epizyme. The data presented on this page does not represent the view of Epizyme and its employees or that of Zippia.
Epizyme may also be known as or be related to EPIZYME INC., Epizyme, Epizyme Inc and Epizyme, Inc.